secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001493152-23-041223
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics reports Q3 net loss of $2.0M; cash increases to $10.1M after business combination
--------------------------------------------------------------------------------

- Net loss of $2.0M ($0.14 per share) for Q3 2023 versus $5.4M loss ($0.63 per share) for Q3 2022.
- R&D expenses rose to $3.3M from $1.9M; G&A decreased to $4.0M from $5.0M.
- Cash and restricted cash of $10.3M as of Sept 30, 2023, versus $0.6M at Dec 31, 2022, reflecting business combination.
- First patient dosed by City of Hope in Phase 1 trial of CLD-101 for recurrent high-grade glioma; interim data expected 1H2024.
- Appointed Andrew Jackson as CFO and Alan Stewart to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315223041223/0001493152-23-041223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315223041223/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-041223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer